Gsk Share Discussion Threads

[toffeeman] 12/3/2018 12:00

Jadetic - because s/he requires that s/he is filtered - simplz

[jadeticl3] 12/3/2018 11:56

Why is buywell3 posting such long articles about prion on this GSK site? Are they relevant?

[gallops] 12/3/2018 11:48

Tradet Michael
My shares have been moved into Smart Investor account, not impressed. Can I ask about transfer to AJ Bell. When transfering portfolo to AJ do Smart sell current holdings at market price and AJ buy at market price. Or does the whole portfolo jusr get transfered to AJ and is there any charge. Thanks for any help.

[fangorn2] 12/3/2018 11:32

Vectura Group and Hikma Pharmaceuticals ;fell on news the US Food & Drug Administration is requesting the completion of an additional clinical endpoint study in relation to development of a generic version of GlaxoSmithKline's Advair Diskus.


Previously, there remained an outstanding issue with the FDA regarding the clinical endpoint study of the generic and, in response, Hikma decided to engage in the FDA's dispute resolution process.

The FDA has now concluded this process, and has upheld its original determination and is requesting the completion of an additional clinical endpoint study. In anticipation of this as one of the potential outcomes, Hikma said it has already finalised the planning of a new clinical study and expects to start patient enrolment in the coming weeks.

Hikma anticipates being able to submit a response to the FDA with new clinical data "as early as possible" in 2019. 

Assuming the successful execution of the new study and a standard regulatory review, we now expect a potential approval and launch during 2020," said Vectura Chief Executive Officer James Ward-Lilley.

[toffeeman] 12/3/2018 09:59

Hi TM (from TM:))

I have been with AJ BEll a while and have encouraged family to open accounts so will be encouraging them to benefit from the IPO as well.

[tradermichael] 12/3/2018 09:21

Following the debacle of the moving of trading accounts from Barclays Stockbrokers to Barclays 'Smart' Investor, I was obliged to move accounts to AJ Bell. The service is superior and the fees are much lower.

I now see that AJ Bell are considering an IPO:

"I am pleased to be able to confirm that we are preparing to list AJ Bell on the London Stock Exchange and that there will be a portion of the initial public offering (IPO) set aside exclusively for AJ Bell customers*.

AJ Bell has been operating for over 22 years now and thanks to the loyal support of our customers, we have grown into one of the largest and most successful investment platforms in the UK, with £42 billion of assets under administration."

[buywell3] 11/3/2018 17:25

More news from Japan about new data re Prion Diseases



Japanese researchers dug through records and identified 22 patients within the country who had developed a specific form of Creutzfeldt-Jakob disease (CJD), a neurodegenerative disease caused by prions, since 2008. These patients had caught CJD from contaminated dura mater grafts (dura mater being a tough membrane that coats the brain and spinal cord) used to help their brains heal after surgery. One patient in particular had their graft implanted in 1985 and only developed CJD 30 years later, in 2015.

The newer cases bring the tally of dura mater graft-associated CJD (dCJD) cases documented in Japan since 1975 up to a total of 154, the authors reported. That represents more than 60 percent of dCJD cases seen worldwide (four have been seen in the US).

[tradermichael] 11/3/2018 07:52

Let's stay with a focus on GSK - it has scored a number of positive RNS updates in the recent weeks, and is set to rise above 1350p quite quickly .... ;0)

[plain sailing] 09/3/2018 12:38

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

[buywell3] 09/3/2018 11:31

New data out


Transmission risk of familial human prion diseases to mice
Date:
March 8, 2018
Source:NIH/National Institute of Allergy and Infectious Diseases

Summary:

Familial human prion diseases are passed within families and are associated with 34 known prion protein mutations. To determine whether three of the unstudied mutations are transmissible, scientists exposed research mice to brain samples from three people who died from a familial prion disease. After observing the mice for about two years, they found two of the mutations, Y226X and G131V, are transmissible.
Share:


Familial human prion diseases are passed within families and are associated with 34 known prion protein mutations. To determine whether three of the unstudied mutations are transmissible, scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, exposed research mice to brain samples from three people who died from a familial prion disease. After observing the mice for about two years, they found two of the mutations, Y226X and G131V, are transmissible.

Perhaps more interesting, the Y226X patient sample had previously been preserved in formaldehyde for three days, embedded in wax, and dried on glass specimen slides for several years before being rehydrated for the study. Yet, the sample infected four of eight mice.


The finding illustrates the hardiness of prion infectivity and the potential risks associated with prion transmission, potentially through surgery, blood transfusion or tissue donation. Samples for the other two mutations studied were taken from frozen brain tissue that was thawed.

Prion diseases originate when normally harmless prion protein molecules become abnormal and gather in clusters and filaments in the human body and brain. The reasons for this process are not fully understood. Familial human prion diseases include genetic Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, and fatal familial insomnia. All are fatal and thus far untreatable. Of the 34 known prion protein mutations, scientists now have tested 13 for transmissibility, identifying nine as transmissible to monkeys or mice.

[juju44] 08/3/2018 17:46

Not doing so well in US

[tradermichael] 08/3/2018 17:41

Yeah ... ;0)

[abdullla] 08/3/2018 16:38

Aren't we all,long may it continue!

[ny boy] 08/3/2018 15:08

Nice quarterly divis & a rise in the share price (long overdue)..i’m Happy 😃

[juju44] 08/3/2018 14:29

Yep , NICE

[ny boy] 08/3/2018 14:24

All good for recovery here.

1370p resistance next medium term target

[tradermichael] 08/3/2018 09:08

GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting (2) -agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting (2) -agonist.
The Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function. No new safety signals were identified and the adverse event data were consistent with the known safety profile for FF/VI established in patients with asthma.
Jonathan Sweeting, SVP and Head of Global Respiratory Franchise GSK, said: Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives. This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."
Dr. Theodore J. Witek Jr., Senior Vice President and Chief Scientific Officer of Innoviva, Inc., added: "The evidence supporting this regulatory update means doctors can be confident that patients taking once-daily Relvar Ellipta will experience comparable benefit in lung function and safety profile, as with a twice-daily ICS/LABA. We welcome this approval, which signifies an important milestone for Relvar Ellipta."
The updated marketing authorisation by the European Commission will be reflected in the label for Relvar Ellipta for countries in the European Union.

[juju44] 07/3/2018 09:43

yesterdays gap got closed - rarely fails

[nico9] 07/3/2018 09:31

cheers TM I will have a read.

[montyhedge] 07/3/2018 09:16

Dow futures not looking good, get ready to batten down the hatches.

[nico9] 07/3/2018 08:58

btw I have read the Intro on the other BB which is interesting on its own especially future Dividends bit

[nico9] 07/3/2018 08:51

reading recent posts. There is talk about a Bid!!! and Pfizer name is also mentioned. Can anyone give a brief summary of Why there is talk of a Bid without me having to trawl back through historic posts etc
Thanks N

[nico9] 07/3/2018 08:31

thanks mate